관련문헌 등
·Persistent Pulmonary Hypertension of the Newborn. NeoReviews an official journal of the American Academy of Pediatrics. 2015
·Kelly LE et al. Sildenafil for pulmonary hypertension in neonates. cochrane review. 4 August 2017.
·Baquero H et al. Oral sildenafil in infants with persistent pulmonary hypertension of the newborn: a pilot randomized blinded study. Pediatrics. 2006 Apr;117(4):1077-83.
·Al Omar S et al. Effect of early adjunctive use of oral sildenafil and inhaled nitric oxide on the outcome of pulmonary hypertension in newborn infants. A feasibility study. J Neonatal Perinatal Med. 2016 Sep 16;9(3):251-9
·Uslu S et al. A comparison of magnesium sulphate and sildenafil in the treatment of the newborns with persistent pulmonary hypertension: a randomized controlled trial. J Trop Pediatr. 2011 Aug;57(4):245-50.
·Vargas-Origel et al. The use of sildenafil in persistent pulmonary hypertension of the newborn. Am J Perinatol. 2010 Mar;27(3):225-30.
·Mulligan C et al. Inhaled iloprost for the control of acute pulmonary hypertension in children: a systematic review. Pediatr Crit Care Med. 2012 Jul;13(4):472-80.
·Kahveci H et al. Oral sildenafil and inhaled iloprost in the treatment of pulmonary hypertension of the newborn. Pediatr Pulmonol. 2014 Dec;49(12):1205-13.
·Kiran More et al. Endothelin receptor antagonists for persistent pulmonary hypertension in term and late preterm infants. cochrane Intervention Review. 2016
·Steinhorn RH et al. Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial. J Pediatr. 2016 Oct;177:90-96.e3
·2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
·Simonneau G et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 Mar 15;165(6):800-4.
·Pulido T et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med 2013; 369:809？-818.
·Coghlan JG et al. Targeting the Prostacyclin Pathway with Selexipag in Patients with Pulmonary Arterial Hypertension Receiving Double Combination Therapy: Insights from the Randomized Controlled GRIPHON Study. Am J Cardiovasc Drugs. 2018 Feb;18(1):37-47.
·Hoeper MM et al. Combining inhaled iloprost with bosentan in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2006 Oct;28(4):691-4.
·McLaughlin VV et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006 Dec 1;174(11):1257-63.
·Han X et al. Treatment of Pulmonary Arterial Hypertension Using Initial Combination Therapy of Bosentan and Iloprost. Respir Care. 2017 Apr;62(4):489-496.
·Strange G et al. Survival of Idiopathic Pulmonary Arterial Hypertension Patients in the Modern Era in Australia and New Zealand. Heart Lung Circ. 2017 Sep 20. pii: S1443-9506(17)31394-X.
·Sitbon O et al. Initial dual oral combination therapy in pulmonary arterial hypertension. Eur Respir J. 2016 Jun;47(6):1727-36.
·Nicole F. Ruopp, et al. Gaps and Controversies of New Treatment Recommendations in Recent Pulmonary Hypertension Guidelines: What We Know and What We Don’t. Advances in Pulmonary Hypertension.(2017)
·William Hopkins, et al. Treatment of pulmonary hypertension in adults, UpToDate Sep 26, 2018.
·Clinical Commissioning Policy Proposition: Selexipag for treating pulmonary arterial hypertension (adults). Prepared by the National Institute for Health and Care Excellence (NICE) Commissioning Support Programme. 2018
·Drugs for Pulmonary Arterial Hypertension: Comparative Efficacy, Safety, and Cost-Effectiveness ―Recommendations Report, March 2015
·Pharmaceutical Benefits Scheme. Post-market Review of Medicines to treat Pulmonary Arterial Hypertension, May 2018